Dan Fitzpatrick, president of stockmarketmentor.com, told Ratigan that some investors are wrong if they believe the bottom has arrived and that it's time to jump in.
Fitzpatrick, a chartologist, said it won't be until late summer that the S&P 500 intersects the 200-day moving average. He said the Nasdaq and tech is where investors want to be because the index is 12% above its November low. And he said there won't be an uptick in oil prices until there is a normal relationship between gold and oil, which is currently decoupled.
In looking at investments outside of stocks, Seymour talked about investing in metals other than gold. For ferrous metals such as iron, he recommends SPDR S&P Metals & Mining ETF (XME). For base metals, he likes Powershares DB Base Metals Fund ETF (DBB).
And for precious metals, he favors PowerShares DB Precious Metals ETF (DBP).In the rising star segment, Najarian touted Crucell (CRXL) as the a great pure play on a vaccine maker. He said the company boasts a great balance sheet, cut costs and jumped 43% in the past 52 weeks. In the final trades, Terranova was for Roche (RHHBY). Adami liked Celgene (CELG). Seymour was up for Stillwater Mining (SWC), and Najarian liked Genentech (DNA). "Check out "'Fast Money' Portfolios of the Week" on Stockpickr every Thursday.